

Synthesis of New Derivatives of 3-Aryl-1,5-dimethyl-1H-[1,2,4]triazolo[4',3':1,2]pyrimido[4,5-e][1,3,4]oxadiazines as Potential Antiproliferative Agents

Mehdi Bakavoli,^{a,*} Mohammad Rahimizadeh,^a Ali Shiri,^a Marzieh Akbarzadeh,^a Seyed-Hadi Mousavi,^{b,c} Zahra Tayarani-Najaran,^b Hoda Atapour-Mashhad,^{c,d} and Mohsen Nikpour^e

^aDepartment of Chemistry, School of Sciences, Ferdowsi University of Mashhad, 91775-1436 Mashhad, Iran

^bDepartment of Pharmacology and Pharmacological Research Centre of Medicinal Plants, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

^cMedical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

^dDepartment of Chemistry, Payam Noor University (PNU), Mashhad, Iran


^eDepartment of Chemistry, School of Sciences, Islamic Azad University, Ahvaz Branch, Ahvaz, Iran

*E-mail: mbakavoli@yahoo.com

Received March 3, 2010

DOI 10.1002/jhet.509

Published online 7 October 2010 in Wiley Online Library (wileyonlinelibrary.com).



Starting from pyrimido[4,5-e][1,3,4]oxadiazines (**3a-c**), a synthetic pathway to [1,2,4]triazolo[4',3':1,2]pyrimido[4,5-e][1,3,4]oxadiazines (**5a-i**) is described. The reaction of pyrimido[4,5-e][1,3,4]oxadiazines (**3a-c**) with hydrazine hydrate afforded the corresponding hydrazino derivatives (**4a-c**). Further treatment of these compounds with different orthoesters in acetic acid gave the corresponding [1,2,4]triazolo[4',3':1,2]pyrimido[4,5-e][1,3,4]oxadiazines (**5a-i**). Compound (**3a**) and (**5b**), as examples, were tested on different cancer cell lines including HeLa, MCF-7, and HepG2. Malignant cells were cultured in DMEM medium and incubated with different concentrations of the titled compounds. Cell viability was quantitated by MTT assay.

J. Heterocyclic Chem., **48**, 183 (2011).

INTRODUCTION


Pyrimidine derivatives and heterocyclic annulated pyrimidines continue to attract great interest because of the wide variety of interesting biological activities observed for these compounds, such as anticancer [1], antiviral [2], antitumor [3], and anti-inflammatory activities [4]. Moreover, triazoles and especially fused triazoles are an important class of heterocyclic compounds with antifungal [5], bactericidal [5,6], anxiolytic [7,8], anticonvulsant [9], herbicidal [10], and antidepressant activities [11]. Keeping this in view, it was thought worthwhile to synthesize the title compounds wherein the biologically active 1,2,4-triazole moieties are fused to potent, pyrimido[4,5-e][1,3,4]oxadiazine ring at 6,7 positions.

Numerous methods for the synthesis of 1,2,4-triazoles have been reported in the literature, which includes utilizing toxic reagents such as phosphorus oxychloride [12], lead tetraacetate [12,13], and bromine [13,14] as

well as other oxidative reagents like chloramines T [15], iodobenzene diacetate [16,17], iron(III) chloride [18], and CuCl_2 [19]. The synthesis of 1,2,4-triazoles through electrochemical method [20] have also been reported. Various triazole derivatives have also been prepared through conversion of iminophosphoranes into triazolo-pyrimidines by initial aza-Wittig reaction between the iminophosphoranes and isocyanate giving a carbodimide as intermediate, which easily undergoes ring closure [21]. Likewise triazoles have been synthesized by refluxing various substituted hydrazonoyl chlorides in the presence of Et_3N for a long time [22] or by treatment of 2-thioxo-1,3,6-trihydropyrimidine-5-carboxylate with appropriate hydrazonoyl halides in boiling CHCl_3 [23].

In continuation of our studies towards the synthesis of fused heterocycles of biological importance containing pyrimidine [24] and oxadiazine [25] moieties, we describe here the synthesis of some new derivatives of 3-aryl-1H-[1,2,4]triazolo[4',3':1,2]pyrimido[4,5-e][1,3,4]oxadiazine (**5a-i**).

Scheme 1



RESULTS AND DISCUSSION

Chemistry. 5-Bromo-2-chloro-6-methyl-4-(1-methylhydrazino)pyrimidine (**2**) was prepared from the reaction of 5-bromo-2,4-dichloro-6-methyl pyrimidine (**1**) with methylhydrazine according to our previous published method [26]. Treatment of the latter compound with aromatic acyl halides in the presence of K_2CO_3 in boiling acetonitrile afforded the pyrimido[4,5-e][1,3,4]oxadiazines (**3a-c**). Subsequent reaction of these compounds with hydrazine led to the replacement of the chlorine atom to give the hydrazino derivatives quantitatively (**4a-c**). The latter products subsequently underwent cyclocondensation with triethyl orthoesters in boiling acetic acid to give the desired tricyclic [1,2,4]triazolo[4',3':1,2]pyrimido[4,5-e][1,3,4]oxadiazines (**5a-i**). (Scheme 1) The structural assignment of compounds (**5a-i**) is based upon spectroscopic and microanalytical data. For example, the 1H -NMR spectrum of (**5b**) did not show the NH_2 and NH signals of the precursor (**4a**) at δ 3.8 and 5.8 ppm, but instead showed a sharp 1H signal at δ 8.3 ppm belonging to the triazole ring indicating the formation of the tricyclic compound (**5b**). The IR spectrum was devoid of the NH_2 and NH absorption bands at $\nu = 3360, 3335,$ and 3260 cm^{-1} of the precursor. The mass spectrum of (**5a**) showed a molecular ion peak at $m/z = 294 (M^+)$ corresponding to the molecular formula $C_{15}H_{14}N_6O$.

Pharmacology. HeLa, MCF-7 and HepG2 were obtained from Pasteur Institute (Tehran, Iran) and maintained at $37^\circ C$ in a humidified atmosphere (90%) containing 5% CO_2 . Cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) with 5% (v/v) fetal

bovine serum, 100 units/mL penicillin, and 100 $\mu g/mL$ streptomycin. Cells were seeded overnight, and then incubated with various concentrations of different extracts for 24 h and 48 h.

For MTT assay, cells were seeded at 5000 cell/well onto 96-well culture plates. For assay of apoptosis, cells were seeded at 100,000 cell/well onto a 24-well plate. For each concentration and time course study, there was a control sample which remained untreated and received the equal volume of medium.

The cell viability was determined using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) assay [27,28]. Briefly, cells were seeded (5000 cell/well) onto flat-bottomed 96-well culture plates and allowed to grow 24 h followed by treatment with a typical heterocyclic derivative (**5b**). After removing the medium, cells were labeled with MTT solution (5 mg/mL in PBS) for 4 h and resulting formazan was dissolved in DMSO (100 μL). The absorption was measured at 570 nm (620 nm as a reference) in an ELISA reader.

To investigate the potential antitumor activities of fused heterocyclic compounds with pyrimidooxadiazine moiety, compound (**3a**) and (**5b**), as example, were selected and tested for their antiproliferative activities in HeLa cell line. Structural changes at the C-7 and the addition of a triazole ring on pyrimido [4,5-e][1,3,4] oxadiazines appear to have a considerable effect on the biological activity. This may indicate that triazole ring is a crucial component of the antiproliferation pharmacophore.

To further improve the antiproliferative activity, our effort was focused on determining the effect of the




Figure 1. Dose-dependent growth inhibition of HeLa cells by compounds **3c** and **5b** (62.5 to 250 μM) for 24 h. Viability was quantitated by MTT assay. The dose inducing 50% cell growth inhibition (IC₅₀) against HeLa was calculated 106.3 μM. Results are Mean ± SEM (n = 3). **P* < 0.05, ***P* < 0.01, and ****P* < 0.001 compared with control (C).

triazole ring. Therefore, the tricyclic compound (**5b**) was also evaluated for its inhibitory activity on HepG2 and MCF-7 cell lines.

Cytotoxicity of compound (**5b**) was examined on malignant cell lines. At first, malignant cells were incubated with various concentrations of (**5b**) (25–400 μM) for 24 h. The result showed compound (**5b**) decreased cell viability of cells as a concentration-dependent manner. The toxicity started as little as 50 μM and during the 24 h, the dose inducing 50% cell growth inhibition (IC₅₀) against HeLa, MCF-7 and HepG2 were calculated 106.3, 555.8, and 294.1 μM, respectively (Figs. 1 and 2).

CONCLUSION

In summary, we have described the synthesis of new 3-aryl-1H-[1,2,4]triazolo[4',3':1,2]pyrimido[4,5-e][1,3,4]oxadiazines (**5a-i**) through heterocyclization of hydrazino derivatives (**4a-c**) with triethylorthoesters in boiling acetic acid. Moreover, we have found that these heterocyclic compounds containing the triazolopyrimidooxadiazine moiety can be considered as a novel class of antiproliferative agents on the basis of a cell-based screening method. Further work is in progress in our laboratory to explain the mechanism of the cell death in cancer cell lines. The results will be reported elsewhere.

EXPERIMENTAL

Melting points were recorded on an Electrothermal type 9100 melting point apparatus and are not corrected. The ¹H-NMR (100 MHz) spectra were recorded on a Bruker AC 100 spectrometer. Chemical shifts are reported in ppm downfield from TMS as internal standard; coupling constants *J* are given in Hertz. The mass

spectra were scanned on a Varian Mat CH-7 at 70 eV. Elemental analysis was performed on a Thermo Finnigan Flash EA micro-analyzer. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT), were purchased from Sigma (St. Louis, MD). RPMI and FCS were purchased from Gibco (Grand Island, NY). General procedure for the synthesis of 3-aryl-7-chloro-1,5-dimethyl-1H-pyrimido[4,5-e][1,3,4]oxadiazine (**3a-c**).

To a magnetically stirred solution of 5-bromo-2-chloro-6-methyl-4-(1-methylhydrazino)pyrimidine(**2**) (1 mmol, 0.25 g) and an appropriate acyl halide (1 mmol) in dry acetonitrile (20 mL), K₂CO₃ (2 mmol, 0.28 g) was added and stirred at room temperature for 1 h. Then, the mixture was refluxed for 6–7 h and the progress of the reaction was monitored by TLC using petroleum ether: ethylacetate (7:3). After the completion of the reaction, the mixture was cooled and the solvent was removed under reduced pressure. Water (5 mL) was added to the resulting precipitate, and the mixture was neutralized by 0.1N HCl solution. The crude solid was filtered and recrystallized from ethanol: water.

7-Chloro-1,5-dimethyl-3-phenyl-1H-pyrimido[4,5-e][1,3,4]oxadiazine (3a). yield = 70%, mp = 156–157°C, ¹H-NMR (CDCl₃, ppm) δ 2.22 (s, 3H, CH₃-pyrimidine), 3.21 (s, 3H, CH₃-N), 7.1–7.8 (m, 5H, phenyl); ir (KBr disc) ν 3010, 2950, 1154 cm⁻¹ (C—O), ms (*m/z*) 274 (M⁺), 276 (M⁺ + 2). Anal. Calcd. for C₁₃H₁₁ClN₄O: C, 56.84; H, 4.04; N, 20.39; Found: C, 55.48; H, 3.20; N, 21.97.

7-Chloro-1,5-dimethyl-3-(4-methylphenyl)-1H-pyrimido[4,5-e][1,3,4]oxadiazine (3b). yield = 60%, mp = 150–151°C, ¹H-NMR (CDCl₃, ppm) δ 2.23 (s, 3H, CH₃-pyrimidine), 2.40 (s, 3H, CH₃-phenyl), 3.21 (s, 3H, CH₃-N), 7.3 (d, *J* = 7 Hz, 2H, phenyl), 7.8 (d, *J* = 7 Hz, 2H, phenyl); ir (KBr disc) ν 3015, 2930, 1152 cm⁻¹ (C—O), ms (*m/z*) 288 (M⁺), 290 (M⁺ + 2). Anal. Calcd. for C₁₄H₁₃ClN₄O: C, 58.24; H, 4.54; N, 19.40; Found: C, 58.32; H, 4.60; N, 19.61.

7-Chloro-3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrimido[4,5-e][1,3,4]oxadiazine (3c). yield = 50%, mp = 175–176°C, ¹H-NMR (CDCl₃, ppm) δ 2.22 (s, 3H, CH₃-pyrimidine), 3.21 (s, 3H, CH₃-N), 7.3 (d, *J* = 8 Hz, 2H, phenyl), 7.7 (d, *J* = 8 Hz, 2H, phenyl); ir (KBr disc) ν 3060, 2950, 1153 cm⁻¹ (C—O), ms (*m/z*)




Figure 2. Dose-dependent growth inhibition of malignant cell lines by compounds **5b** (25 to 400 μM) for 24 h. Viability was quantitated by MTT assay. The dose inducing 50% cell growth inhibition (IC₅₀) against Hep-G2 and MCF-7 was calculated 294.1 and 555.8 μM, respectively. Results are Mean ± SEM (n = 3). **P* < 0.05, ***P* < 0.01, and ****P* < 0.001 compared with control (C).

Table 1

Physical, spectral, and microanalytical data of 3-aryl-1H-[1,2,4]triazolo[4',3':1,2]pyrimido[4,5-e][1,3,4]oxadiazine (5a-i).

Entry	Yield (%)	mp (°C)	Spectral data ^a	Molecular formula	C% (Calcd)	H% (Calcd)	N% (Calcd)
5a	65	270–271	¹ H NMR: δ 2.19 (s, 3H, CH ₃ -pyrimidine), 3.45 (s, 3H, CH ₃ -N), 7.42–7.83 (m, 5H, ph), 8.33 (s, 1H, triazol). ir: ν 3005, 2920, 1610, 1550, 1490, 1005 cm ⁻¹ , <i>m/z</i> 280 (M ⁺).	C ₁₄ H ₁₂ N ₆ O	59.89 (59.99)	4.30 (4.32)	29.88 (29.98)
5b	72	324–326	¹ H NMR: δ 2.60 (s, 3H, CH ₃ -pyrimidine), 2.75 (s, 3H, CH ₃ -triazol), 3.42 (s, 3H, CH ₃ -N), 7.32–7.81 (m, 5H, ph), ir: ν 3000, 2900, 1610, 1550, 1490, 1005 cm ⁻¹ , <i>m/z</i> 294 (M ⁺).	C ₁₅ H ₁₄ N ₆ O	61.10 (61.22)	4.72 (4.79)	28.48 (28.55)
5c	50	330	¹ H NMR: δ 1.53 (t, 3H, CH ₃), 2.64 (s, 3H, CH ₃ -pyrimidine), 3.25 (q, 2H, CH ₂ -triazol), 3.51 (s, 3H, CH ₃ -N), 7.43–7.94 (m, 5H, ph). ir: ν 3015, 2940, 1605, 1555, 1500, 1015 cm ⁻¹ , <i>m/z</i> 308 (M ⁺).	C ₁₆ H ₁₆ N ₆ O	62.21 (62.32)	5.17 (5.23)	27.03 (27.26)
5d	74	290–291	¹ H NMR: δ 2.42 (s, 3H, CH ₃ -pyrimidine), 2.50 (s, 3H, CH ₃ -ph), 3.47 (s, 3H, CH ₃ -N), 7.27 (d, <i>J</i> = 7.5 Hz, 2H, ph), 7.70 (d, <i>J</i> = 7.5 Hz, 2H, ph), 8.32 (s, 1H, triazol). ir: ν 3000, 2950, 1605, 1540, 1480, 1000 cm ⁻¹ , <i>m/z</i> 294 (M ⁺).	C ₁₅ H ₁₄ N ₆ O	61.14 (61.21)	4.68 (4.79)	28.45 (28.55)
5e	68	314	¹ H NMR: δ 2.42 (s, 3H, CH ₃ -pyrimidine), 2.59 (s, 3H, CH ₃ -ph), 2.75 (s, 3H, CH ₃ -triazol), 3.42 (s, 3H, CH ₃ -N), 7.32 (d, <i>J</i> = 7.5 Hz, 2H, ph), 7.73 (d, <i>J</i> = 7.5 Hz, 2H, ph). ir: ν 3010, 2910, 1630, 1560, 1500, 1020 cm ⁻¹ , <i>m/z</i> 308 (M ⁺).	C ₁₆ H ₁₆ N ₆ O	62.29 (62.32)	5.17 (5.23)	27.20 (27.26)
5f	46	340–343	¹ H NMR: δ 1.43 (t, 3H, CH ₃), 2.43 (s, 3H, CH ₃ -pyrimidine), 2.60 (s, 3H, CH ₃ -ph), 2.75 (s, 3H, CH ₃ -triazol), 3.42 (s, 3H, CH ₃ -N), 7.34 (d, <i>J</i> = 7.5 Hz, 2H, ph), 7.73 (d, <i>J</i> = 7.5 Hz, 2H, ph). ir: ν 3015, 2920, 1620, 1565, 1515, 1025 cm ⁻¹ , <i>m/z</i> 322 (M ⁺).	C ₁₇ H ₁₈ N ₆ O	63.31 (63.34)	5.57 (5.63)	25.89 (26.07)
5g	62	293–295	¹ H NMR: δ 2.44 (s, 3H, CH ₃ -pyrimidine), 3.30 (s, 3H, CH ₃ -N), 7.52 (d, <i>J</i> = 7.3 Hz, 2H, ph), 7.91 (d, <i>J</i> = 7.3 Hz, 2H, ph), 8.82 (s, 1H, triazol). ir: ν 3050, 2900, 1625, 1560, 1480, 1010 cm ⁻¹ , <i>m/z</i> 314 (M ⁺), 316 (M ⁺ + 2).	C ₁₄ H ₁₁ ClN ₆ O	53.40 (53.43)	3.48 (3.52)	26.65 (26.70)
5h	57	319–320	¹ H NMR: δ 2.44 (s, 3H, CH ₃ -pyrimidine), 2.76 (s, 3H, CH ₃ -triazol), 3.30 (s, 3H, CH ₃ -N), 7.53 (d, <i>J</i> = 7.3 Hz, 2H, ph), 7.94 (d, <i>J</i> = 7.3 Hz, 2H, ph), ir: ν 3090, 2990, 1650, 1600, 1550, 1490, 1080 cm ⁻¹ , <i>m/z</i> 328 (M ⁺), 330 (M ⁺ + 2).	C ₁₅ H ₁₃ ClN ₆ O	54.76 (54.80)	3.87 (3.99)	25.54 (25.56)
5i	41	331–333	¹ H NMR: δ 1.53 (t, 3H, CH ₃), 2.44 (s, 3H, CH ₃ -pyrimidine), 2.88 (q, 2H, CH ₂), 3.30 (s, 3H, CH ₃ -N), 7.53 (d, <i>J</i> = 7.3 Hz, 2H, ph), 7.95 (d, <i>J</i> = 7.3 Hz, 2H, ph). ir: ν 3100, 2950, 1660, 1590, 1550, 1470, 1065 cm ⁻¹ , <i>m/z</i> 342 (M ⁺), 344 (M ⁺ + 2).	C ₁₆ H ₁₅ ClN ₆ O	55.98 (56.06)	4.39 (4.41)	24.47 (24.52)

^aThe solvent for ¹H NMR is CDCl₃ and the chemical shifts are in ppm.

308 (M⁺), 310 (M⁺ + 2), 312 (M⁺ + 4). Anal. Calcd. for C₁₃H₁₀Cl₂N₄O: C, 50.51; H, 3.26; N, 18.12; Found: C, 50.60; H, 3.23; N, 18.15.

General procedure for the preparation of 3-aryl-1,5-dimethyl-7-hydrazino-1H-pyrimido[4,5-e][1,3,4]oxadiazine (4a-c). To a solution of 3-aryl-1,5-dimethyl-7-chloro-1H-pyrimido[4,5-e][1,3,4]oxadiazine (3a-c) (3.7 mmol) in ethanol (20 mL), hydrazine hydrate (2 mL) was added, and the solution was refluxed for 5 h. The resulting precipitate was filtered off and recrystallized from ethanol.

1,5-Dimethyl-7-hydrazino-3-phenyl-1H-pyrimido[4,5-e][1,3,4]oxadiazine (4a). yield = 77%, mp = 200–202°C, ¹H-NMR (DMSO-*d*₆, ppm): δ 2.21 (s, 3H, CH₃), 3.22 (s, 3H, CH₃-N), 3.95 (br s, 2H, NH₂, D₂O exchangeable), 5.93 (br s, 1H, NH, D₂O exchangeable), 7.31–7.50 (m, 3H, Ph), 7.74–7.89 (m, 2H, Ph); ir (KBr disc) ν 3360, 3335, 3260, 1115 cm⁻¹; ms (*m/z*) 270 (M⁺); Anal. Calcd. for C₁₃H₁₄N₆O (%): C, 57.77; H, 5.22; N, 31.09. Found: C, 57.73; H, 5.05; N, 30.89.

1,5-Dimethyl-7-hydrazino-3-(4-methylphenyl)-1H-pyrimido[4,5-e][1,3,4]oxadiazine (4b). yield = 68%, mp = 196–198°C, ¹H-NMR (DMSO-*d*₆, ppm): δ 2.19 (s, 3H, CH₃), 2.38 (s, 3H,

CH₃), 3.21 (s, 3H, CH₃), 3.85 (br s, 2H, NH₂, D₂O exchangeable), 5.89 (br s, 1H, NH, D₂O exchangeable), 7.21 (d, *J* = 7.7 Hz, 2H, Ph), 7.69 (d, *J* = 7.7 Hz, 2H, Ph); ir (KBr disc) ν 3345, 3270, 3260, 1110 cm⁻¹; ms (*m/z*) 284 (M⁺); Anal. Calcd. for C₁₄H₁₆N₆O (%): C, 59.14; H, 5.67; N, 29.56. Found: C, 59.06; H, 5.64; N, 29.45.

3-(4-Chlorophenyl)-1,5-dimethyl-7-hydrazino-1H-pyrimido[4,5-e][1,3,4]oxadiazine (4c). yield = 72 %, mp = 241–243°C, ¹H-NMR (DMSO-*d*₆, ppm): δ 2.19 (s, 3H, CH₃), 3.20 (s, 3H, CH₃), 3.89 (br s, 2H, NH₂, D₂O exchangeable), 5.92 (br s, 1H, NH, D₂O exchangeable), 7.35 (d, *J* = 7.9 Hz, 2H, Ph), 7.73 (d, *J* = 7.9 Hz, 2H, Ph); ir (KBr disc) ν 3320, 3305, 3280, 1105 cm⁻¹; ms (*m/z*) 304 (M⁺), 306 (M⁺ + 2); Anal. Calcd. for C₁₃H₁₃ClN₆O (%): C, 51.24; H, 4.30; N, 27.58. Found: C, 51.14; H, 4.22; N, 27.51.

General procedure for the synthesis of 3-aryl-1,5-dimethyl-1H-[1,2,4]triazolo[4',3':1,2]pyrimido[4,5-e][1,3,4]oxadiazines (5a-i). To a solution of 3-aryl-1,5-dimethyl-7-hydrazino-1H-pyrimido[4,5-e][1,3,4]oxadiazine (4a-c) (1 mmol) in HOAc (2 mL), the respective triethylorthoester (2 mmol) was added. The reaction solution was heated under reflux for 4 h.

After the completion of the reaction which was monitored by TLC using chloroform: methanol (9:1), the mixture was cooled to room temperature. Water (5 mL) was added and the mixture was neutralized by saturated NaHCO₃ solution. The collected solid was recrystallized from ethanol (Table 1).

REFERENCES AND NOTES

- [1] Petrie, C. R.; Cottam, H. B.; Mckernan, P. A.; Robins, P. K.; Revankar, G. R. *J Med Chem* 1985, 28, 1010.
- [2] Nasr, M. N.; Gineinah, M. M. *Arch Pharm* 2002, 335, 289.
- [3] Baraldi, P. G.; Pavani, M. G.; Nunez, M.; Brigidi, P.; Vitali, B.; Gambari, R.; Romagnoli, R. *Bioorg Med Chem* 2002, 10, 449.
- [4] Sondhi, S. M.; Johar, M.; Rajvanshi, S.; Dastidar, S. G.; Shukla, R.; Raghbir, R.; Lown, J. W. *Aust J Chem* 2001, 54, 69.
- [5] El-Hawash, S. A.; Habib, N. S.; Fanaki, N. H. *Pharmazie* 1999, 54, 808.
- [6] Brown, D. J.; Iwai, Y. *Aust J Chem* 1979, 32, 2727.
- [7] Tarzia, G.; Ocelli, E.; Toja, E.; Barone, D.; Corsico, N.; Gallico, L.; Luzzani, F.; *J Med Chem* 1988, 31, 1115.
- [8] Trust, R. I.; Albright, J. D. U.S. Pat. 4,242,515, (1980)(Trust, R. I.; Albright, J. D. *Chem Abstr* 1981, 94:139815d).
- [9] Tarzia, G.; Ocelli, E.; Barone, D. *Farmaco* 1989, 44, 3.
- [10] (a) Peignier, R.; Chene, A.; Cantregil, R.; Mortier, J. Eur. Pat. 441718 (1991); *Chem Abstr* 1991, 115:208000; (b) Cantregil, R.; Chene, A.; Mortier, J.; Peignier, R. Eur. Pat. 483027 (1992); *Chem Abstr* 1992, 117:131214.
- [11] Sarges, S.; Howard, H. R.; Browne, R. G.; Lebel, L. A.; Seymour, P. A.; Koe, B. K. *J Med Chem* 1990, 33, 2240.
- [12] Bower, J. D.; Doyle, F. P. *J Chem Soc* 1957, 2240.
- [13] Pollak, A.; Tisler, M. *Tetrahedron* 1966, 22, 2073.
- [14] Gibson, M. S. *Tetrahedron* 1963, 19, 1587.
- [15] Bourgeois, P.; Cantregil, R.; Chene, A.; Gelin, J.; Mortier, J.; Moyroud, J. *Synth Commun* 1993, 23, 3195.
- [16] Sadana, A. K.; Mirza, Y.; Aneja, K. R.; Prakash, O. *Eur J Med Chem* 2003, 38, 533.
- [17] Kumar, D.; Kondapalli, V. G.; Chandra, S.; Harmeet, D.; Vajja, S. R.; Rajender, S. *Green Chem* 2004, 6, 156.
- [18] Shawali, A. S.; Hassaneen, H. M.; Shurrab, N. K. *Tetrahedron* 2008, 64, 10339.
- [19] Ciesielski, M.; Pufky, D.; Doring, M. *Tetrahedron* 2005, 61, 5942.
- [20] Crljenak, S.; Tabakovic, I.; Jeremic, D.; Gaon, I. *Acta Chem Scand* 1983, B37, 527.
- [21] Ding, M. W.; Huang, N. Y.; He, H. W. *Synthesis* 2005, 10, 1601.
- [22] El-Gazzar, A. B. A.; El-Enany, M. M.; Mahmoud, M. N. *Bioorg Med Chem* 2008, 16, 3261.
- [23] Abdelhamid, A. O.; Sayed, A. R.; Zaki, Y. H. *Phosphorus Sulfur Silicon* 2007, 182, 1447.
- [24] (a) Rahimizadeh, M.; Nikpour, M.; Bakavoli, M. *J Heterocycl Chem* 2007, 44, 463; (b) Bakavoli, M.; Nikpour, M.; Rahimizadeh, M.; Saberi, M. R.; Sadeghian, H., *Bioorg Med Chem* 2007, 15, 2120; (c) Bakavoli, M.; Raisi, H.; Tajabadi, J.; Karimi, M. *J Sulfur Chem* 2008, 29, 25; (d) Bakavoli, M.; Sadeghian, H.; Tabatabaei, Z.; Rezaei, E.; Rahimizadeh, M.; Nikpour, M. *J Mol Mod* 2008, 14, 471; (e) Bakavoli, M.; Rahimizadeh, M.; Shiri, A.; Eshghi, H.; Nikpour, M. *Heterocycles* 2008, 75, 1745; (f) Bakavoli, M.; Bagherzadeh, G.; Vaseghifar, M.; Shiri, A.; Pordel, M.; Mashreghi, M.; Pordeli, P.; Araghi, M. *Eur J Med Chem* 2010, 45, 647; (g) Bakavoli, M.; Bagherzadeh, G.; Vaseghifar, M.; Shiri, A.; Pordeli, P. *J Chem Res* 2009, 653.
- [25] Bakavoli, M.; Rahimizadeh, M.; Shiri, A.; Eshghi, H.; Pordeli, P.; Pordel, M.; Nikpour, M. *J Heterocycl Chem* 2011, 48, 149.
- [26] Bakavoli, M.; Nikpour, M.; Rahimizadeh, M. *J Heterocycl Chem* 2006, 43, 1327.
- [27] Mosmann, T. *J Immunol Methods* 1983, 16, 55.
- [28] Mousavi, S. H.; Tavakkol-Afshari, J.; Brook, A.; Jafari-Anarkooli, I. *Food Chem Toxicol* 2009, 47, 855.